Related Experiment Video
Updated: Jan 18, 2026
siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
Published on: October 28, 2019
Inhibition of herpes simplex virus infection by Caesappanin C targeting virus gB protein and host HSP90β
Jiayi Yang1, Jie Wang1, Han Yan2
1Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Background:
The increasing drug resistance and limitations of conventional anti-herpes simplex virus (HSV) drugs highlight the urgent need for safer and more effective alternatives. Caesappanin C (CAP), derived from Caesalpinia sappan L., is recognized for its diverse biological properties, but its efficacy against HSV remains unexplored.
Purpose:
To assess CAP's anti-HSV efficacy in vitro and in vivo, and to clarify its mechanisms.
Methods:
CAP's anti-HSV activity in vitro was assessed using western blot, immunofluorescence assay and plaque assay. The anti-HSV mechanisms of CAP were investigated using membrane fusion, Co-IP and DARTS assays. Murine models of HSV-1 intranasal infection model and HSV-2 genital herpes model were used to evaluate CAP's activity in vivo.
Results:
CAP inhibited HSV replication across multiple cell types with minimal toxicity. CAP can effectively deactivate HSV particles and bind HSV surface glycoprotein B (gB) to inhibit membrane fusion. CAP also interacted with HSP90β to reduce the binding of HSP90β to STING thereby reducing HSV-induced inflammatory response. Furthermore, CAP markedly enhanced survival rates and alleviated inflammation in HSV-infected mice.
Conclusion:
CAP effectively inhibits HSV by binding gB to prevent viral entry and interacting with HSP90β to diminish inflammatory responses. These results indicate that CAP derived from Caesalpinia sappan L. may have the potential to be an effective drug candidate against HSV.
